Zymeworks is a fast-growing biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for treatment of cancer and autoimmune diseases. Zymeworks is proud to have active collaborations with both Merck & Co., Inc. and Eli Lilly and Company, and is committed to making a meaningful difference in the lives of patients everywhere. Our lab activities are outsourced - we use leading global labs, CROs and CMOs.